Review
Gastroenterology & Hepatology
Omar Alshuwaykh, Paul Y. Kwo
Summary: Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma globally. While treatment has been successful in the past, challenges in diagnosis and treatment remain, making global elimination of hepatitis C problematic. Multiple populations are being targeted for care models and efforts for a vaccine continue.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Bernhard Schlevogt, Klaus H. W. Boeker, Stefan Mauss, Hartwig Klinker, Renate Heyne, Ralph Link, Karl-Georg Simon, Christoph Sarrazin, Yvonne Serfert, Michael P. Manns, Heiner Wedemeyer
Summary: The study indicates that patients receiving interferon-free antiviral treatment for chronic hepatitis C experience significant weight gain during long-term follow-up, with non-obese patients being more vulnerable to weight gain. A body mass index (BMI) < 30 was the only consistent predictor for weight gain, suggesting that non-obese individuals are more likely to gain weight after DAA treatment.
Article
Public, Environmental & Occupational Health
S. Mondschein, N. Yankovic, O. Matus
Summary: The study developed a patient prioritization scheme for treating HCV patients in Spain and Chile, showing that the new prioritization scheme outperformed current practices in terms of cost and healthcare indicators when resources are limited.
Review
Virology
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen
Summary: Ropeginterferon alfa-2b is a promising treatment option for MPN and chronic viral hepatitis due to its favorable pharmacokinetic profile and demonstrated efficacy in clinical studies. Administered once every two weeks, it has shown to be well-tolerated and effective in treating chronic hepatitis B, C, and D.
Article
Pharmacology & Pharmacy
Leandro Francisco Pippa, Carolina Pinto Vieira, Juciene Aparecida Caris, Adriana Rocha, Camile Prates Garcia, Rosamar Eulira Fontes Rezende, Vera Lucia Lanchote
Summary: This study assessed the effect of chronic hepatitis C on CYP2C19 activity and found that the metabolic ratios of patients in groups 1 and 2 changed after treatment with direct-acting antivirals, indicating partial reversal of CYP2C19 inhibition during inflammation.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Immunology
A. E. Ades, Fabiana Gordon, Karen Scott, Intira Jeannie Collins, Claire Thorne, Lucy Pembrey, Elizabeth Chappell, Eugenia Marine-Barjoan, Karina Butler, Giuseppe Indolfi, Diana M. Gibb, Ali Judd
Summary: Based on the largest purely prospective dataset assembled to date, this study found that 66% of confirmed vertically acquired hepatitis C virus infections clear spontaneously by age 5 years, rather than the 25%-40% assumed in current guidelines. Treatment before age 3 would avoid loss to follow-up but result in substantial overtreatment.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Public, Environmental & Occupational Health
Jinyu Liu, Min Guo, Lei Ke, Ruxu You
Summary: The economic evaluation of elbasvir/grazoprevir (EBR/GZR) for chronic hepatitis C (CHC) shows that EBR/GZR may be cost-effective or dominant compared with pegylated interferon and ribavirin (PegIFN/RBV) and other direct antiviral agents (SOF/VEL, 3D, DCV/ASV, LDF/SOF) or non-therapy. However, in certain scenarios, EBR/GZR is not a cost-effective option for CHC patients compared to glecaprevir/pibrentasvir (GLE/PIB).
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Gastroenterology & Hepatology
Futa Kida, Anju Murayama, Hiroaki Saito, Akihiko Ozaki, Yuki Shimada, Tetsuya Tanimoto
Summary: This study examined the payments made by pharmaceutical companies to the authors of the Hepatitis C Clinical Practice Guidelines and the financial conflicts of interest reported by the authors. The results showed that all authors received payments from pharmaceutical companies, with a strong relationship to the companies manufacturing DAAs.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Natalia Konstantelos, Ahmad Shakeri, Daniel McCormack, Jordan J. Feld, Tara Gomes, Mina Tadrous
Summary: The study found that COVID-19 related healthcare restrictions significantly decreased the number of individuals dispensed with DAAs by 49.3%. Further research is needed to explore the long-term effects of reduced treatment on patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Gastroenterology & Hepatology
Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim
Summary: Hepatitis C virus (HCV) infection is the second leading cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and the incidence increases with age. The underdiagnosis of HCV is a major barrier to elimination, and universal screening for HCV in adults has been suggested to improve detection. Recent studies have shown that universal screening and treatment using direct-acting antivirals are cost-effective approaches for prevention and treatment of HCV infection.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Article
Immunology
Sabin Nsanzimana, Michael J. Penkunas, Carol Y. Liu, Dieudonne Sebuhoro, Alida Ngwije, Eric Remera, Justine Umutesi, Cyprien Ntirenganya, Soline D. Mugeni, Janvier Serumondo
Summary: This study examined the effectiveness of DAAs in patients treated through the Rwandan national health system and identified factors associated with treatment outcomes. Results showed that DAAs were effective in achieving SVR12 in a majority of patients, but higher pretreatment HCV RNA levels were associated with virological failure. Additionally, patients in Western Province were more likely to experience nonvirological failure due to longer travel time for testing and treatment.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Health Care Sciences & Services
L. Madeline Mccrary, Kate E. Roberts, Mary Catherine Bowman, Briana Castillo, Jama M. Darling, Christine Dunn, Robyn Jordan, Jane E. Young, Asher J. Schranz
Summary: This study aimed to improve retention in hepatitis C (HCV) care among hospitalized people who inject drugs (PWID). The program, which included e-consultation-prompted care coordination and outpatient telehealth for HCV treatment, achieved favorable outcomes for hospitalized PWID.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2023)
Article
Management
Susana Mondschein, Natalia Yankovic, Omar Matus
Summary: The study utilizes stochastic dynamic programming to determine the optimal policy for prescribing new hepatitis C treatments, showing that only patients meeting specific criteria should receive the new drugs, leading to significant reductions in overall expenditure. A method to prioritize patients during budget constraints is also proposed to address shortage or surplus issues.
INTERNATIONAL TRANSACTIONS IN OPERATIONAL RESEARCH
(2021)
Article
Infectious Diseases
Szu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu
Summary: Elbasvir/Grazoprevir (EBR/GZR) is an effective combination of direct-acting antiviral drugs, proven to be effective in HCV GT1, 4 infections. It has a higher barrier to resistance-associated substitutions and is well tolerated in clinical treatment.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2021)
Article
Immunology
Lone Wulff Madsen, Peer Brehm Christensen, Anne Ovrehus, Dorthe Marie Sjodahl Bryde, Dorte Kinggaard Holm, Soren Thue Lillevang, Christian Nielsen
Summary: Reducing treatment duration for chronic hepatitis C is important for achieving elimination goals. This exploratory study examines immune subsets in patients who achieved SVR12 or experienced virological relapse following four weeks treatment with glecaprevir/pibrentasvir with or without ribavirin.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Reina Sasaki-Tanaka, Toshikatsu Shibata, Hiroaki Okamoto, Mitsuhiko Moriyama, Tatsuo Kanda
Summary: In this study, several novel therapeutic drugs were investigated through a drug repositioning approach, with favipiravir identified as a potential antiviral against hepatitis A virus (HAV) infection. The study examined the replication of HAV and introduced nucleotide mutations in the HAV genome using different drugs. Favipiravir showed inhibitory effects on HAV replication and introduced more nucleotide mutations compared to ribavirin. Further in vivo experiments are needed to confirm the efficacy of favipiravir in treating severe HAV infection.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Naoki Matsumoto, Masahiro Ogawa, Masahiro Kaneko, Shuhei Arima, Mariko Kumagawa, Yukinobu Watanabe, Midori Hirayama, Ryota Masuzaki, Tatsuo Kanda, Mitsuhiko Moriyama
Summary: This study aimed to compare the blood flow detectability of CEUS, CT, and MRI in hepatocellular carcinoma during lenvatinib therapy. Results showed that CEUS was more effective in detecting blood flow than CT and MRI, which can help confirm the viability of the tumor.
JOURNAL OF MEDICAL ULTRASONICS
(2022)
Review
Oncology
Ryota Masuzaki, Tatsuo Kanda, Reina Sasaki, Naoki Matsumoto, Kazushige Nirei, Masahiro Ogawa, Seth J. Karp, Mitsuhiko Moriyama, Hirofumi Kogure
Summary: Hepatocellular carcinoma (HCC) is a common malignancy worldwide and the SOCS family proteins play an important role in HCC development and liver regeneration. By negatively regulating cytokine signaling, SOCS proteins can modulate cellular growth, differentiation, and immune response. In HCC treatment, SOCS proteins may be potential targets for controlling cell proliferation and immune response.
Editorial Material
Biochemistry & Molecular Biology
Tatsuo Kanda, Reina Sasaki-Tanaka, Shingo Nakamoto
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Hiroaki Kanzaki, Tetsuhiro Chiba, Tatsuya Kaneko, Junjie Ao, Motoyasu Kan, Ryosuke Muroyama, Shingo Nakamoto, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Yoh Zen, Ai Kotani, Kazuma Sekiba, Motoyuki Otsuka, Masayuki Ohtsuka, Naoya Kato
Summary: ELAVL1 protein is not only involved in the replication of hepatitis B virus, but also has an impact on the cell growth of hepatocellular carcinoma, making it a potential therapeutic target for HBV-related HCC treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Terunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, Tatsuya Kaneko, Junjie Ao, Na Qiang, Yaojia Ma, Jiaqi Zhang, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Motoyasu Kan, Miyuki Nakagawa, Kisako Fujiwara, Naoto Fujita, Takafumi Sakuma, Hiroaki Kanzaki, Keisuke Koroki, Yuko Kusakabe, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Shingo Nakamoto, Ryosuke Muroyama, Jun Kato, Tatsuo Kanda, Hitoshi Maruyama, Naoya Mimura, Takuya Honda, Toshihiko Murayama, Hiroyuki Nakamura, Naoya Kato
Summary: This study demonstrates that miglustat can suppress liver fibrosis by inhibiting the TGF-5/Smad pathway, reducing the expression of extracellular matrix components such as collagen. The research also shows that miglustat can both prevent the occurrence of liver fibrosis and reverse established fibrosis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Keiichi Fujiwara, Shin Yasui, Takayuki Kondo, Masato Nakamura, Makoto Arai, Tatsuo Kanda, Osamu Yokosuka, Masayuki Ohtsuka, Ryuzo Abe, Naoya Kato
Summary: The prognosis of patients with fulminant hepatitis and late-onset hepatic failure in Japan has not improved over the past 32 years, despite advancements in clinical management and liver transplantation. The increasing proportion of patients with poor prognosis and difficult-to-treat etiologies, as well as the aging population, may contribute to this lack of improvement.
HEPATOLOGY RESEARCH
(2023)
Article
Virology
Reina Sasaki-Tanaka, Ryota Masuzaki, Hiroaki Okamoto, Toshikatsu Shibata, Mitsuhiko Moriyama, Hirofumi Kogure, Tatsuo Kanda
Summary: This study identified nicotinamide as a potential therapeutic drug for HAV infection by inhibiting HAV replication through suppressing AP-1 activity and HAV IRES-mediated translation.
JOURNAL OF VIROLOGY
(2023)
Article
Surgery
Hayato Abe, Kazu Shibutani, Shintaro Yamazaki, Tatsuo Kanda, Mitsuhiko Moriyama, Masahiro Okada, Masahiko Sugitani, Shingo Tsuji, Tadatoshi Takayama, Yukiyasu Okamura
Summary: This study aimed to investigate the predictive value of preoperative tumor stiffness measured by magnetic resonance elastography on overall survival and recurrence-free survival in patients with hepatocellular carcinoma. The results showed that higher tumor stiffness was associated with increased risk of recurrence and death.
Article
Oncology
Keita Ogawa, Tetsuhiro Chiba, Masato Nakamura, Jun Arai, Jiaqi Zhang, Yaojia Ma, Na Qiang, Junjie Ao, Sae Yumita, Takamasa Ishino, Motoyasu Kan, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Hiroaki Kanzaki, Keisuke Koroki, Yuko Kusakabe, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Ryosuke Muroyama, Shingo Nakamoto, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Shoji Matsumoto, Takayoshi Arai, Shinichiro Motohashi, Naoya Kato
Summary: In this study, the inhibition of ADAM9 was found to prevent the release of MICA and activate the immune function of NK cells. Through the screening of a chemical library, a compound called CCL347 with five benzene rings was identified, which significantly reduced sMICA levels in HCC cell lines and enhanced NK cell cytotoxicity, indicating its potential as a novel therapeutic drug for HCC.
ANTICANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Reina Sasaki-Tanaka, Toshikatsu Shibata, Mitsuhiko Moriyama, Hirofumi Kogure, Asuka Hirai-Yuki, Hiroaki Okamoto, Tatsuo Kanda
Summary: In this study, HuhT7-HAV/Luc cells were established as a suitable model for anti-HAV drug screening. Masitinib, a tyrosine kinase inhibitor, was found to reduce HAV replication and internal ribosomal entry-site (IRES) activity. It may be a potential treatment for severe HAV infection.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Tatsuo Kanda, Ryota Masuzaki, Reina Sasaki-Tanaka, Hirofumi Kogure, Mitsuhiko Moriyama
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Biochemistry & Molecular Biology
Tatsuo Kanda
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Shini Kanezawa, Mitsuhiko Moriyama, Tatsuo Kanda, Akiko Fukushima, Ryota Masuzaki, Reina Sasaki-Tanaka, Akiko Tsunemi, Takahiro Ueno, Noboru Fukuda, Hirofumi Kogure
Summary: Metabolic-dysfunction-associated fatty-liver disease (MAFLD) is the leading cause of liver disease worldwide. Nonalcoholic steatohepatitis (NASH) patients have a higher prevalence of small-intestinal bacterial overgrowth (SIBO). In this study, we investigated the differences in gut microbiota between stroke-prone spontaneously hypertensive-5 rats (SHRSP5) fed a normal diet (ND) or a high-fat- and high-cholesterol-containing diet (HFCD). We found an association between MAFLD and gut microbiota alteration, suggesting that targeting gut microbiota may be a potential therapeutic approach for MAFLD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Tatsuo Kanda, Reina Sasaki-Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, Tian-Cheng Li, Satoshi Kunita, Hiroshi Yotsuyanagi, Hiroaki Okamoto
Summary: The Japan Agency for Medical Research and Development (AMED) Hepatitis A and E viruses (HAV and HEV) Study Group has reviewed the recent advances in HAV research and clinical practice for HAV infection in Japan and authored comprehensive guidelines. The article covers virological findings, clinical presentation, pathogenicity, diagnostic approaches, complications, risk factors, preventive measures, and treatment modalities for hepatitis A.
HEPATOLOGY RESEARCH
(2023)